MET Overexpression

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Alveolar Rhabdomyosarcoma1
MET Overexpression AND ALK Overexpression	Crizotinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID7136 Since significant ALK and MET expression was only detected in ARMS samples, the effect of crizotinib, an ATP competitive, MET and ALK inhibitor, was evaluated on the growth of RH4 and RH30 ARMS cell l… (full text at CIViC) PMID 26445453 · Megiorni et al., 2015 · Open in CIViC	civic
Clear Cell Sarcoma of Soft Tissue1
MET Overexpression AND EWSR1::ATF1 Fusion	Crizotinib	Predictive	B	Supports Sensitivity Response	2	submitted	EID11455 28 patients were selected from a cohort of 43 patients with clear-cell sarcoma (CCSA) for this phase II trial. 26 of such patients presented with EWSR1 rearrangement and MET overexpression (MET+ cohor…

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Alveolar Rhabdomyosarcoma1

MET Overexpression AND ALK Overexpression

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID7136

Since significant ALK and MET expression was only detected in ARMS samples, the effect of crizotinib, an ATP competitive, MET and ALK inhibitor, was evaluated on the growth of RH4 and RH30 ARMS cell l… (full text at CIViC)

PMID 26445453 · Megiorni et al., 2015 · Open in CIViC

civic

Clear Cell Sarcoma of Soft Tissue1

MET Overexpression AND EWSR1::ATF1 Fusion

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID11455

28 patients were selected from a cohort of 43 patients with clear-cell sarcoma (CCSA) for this phase II trial. 26 of such patients presented with EWSR1 rearrangement and MET overexpression (MET+ cohor…

Cutaneous Melanoma2
MET Overexpression	Vemurafenib	Predictive	B	Supports Resistance	4	accepted	EID1581 Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were ana… (full text at CIViC) PMID 26359985 · Hugo et al., 2015 · Open in CIViC	civic
MET Overexpression	Vemurafenib	Predictive	B	Does Not Support Resistance	3	accepted	EID1584 FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET … (full text at CIViC) PMID 23802768 · Jubb et al., 2013 · Open in CIViC	civic

Cutaneous Melanoma2

MET Overexpression

Vemurafenib

Predictive

Supports Resistance

accepted

EID1581

Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were ana… (full text at CIViC)

PMID 26359985 · Hugo et al., 2015 · Open in CIViC

civic

MET Overexpression

Vemurafenib

Predictive

Does Not Support Resistance

accepted

EID1584

FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET … (full text at CIViC)

PMID 23802768 · Jubb et al., 2013 · Open in CIViC

civic

Gastric Adenocarcinoma1
MET Overexpression	Rilotumumab	Predictive	B	Does Not Support Sensitivity Response	5	accepted	EID5835 In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarc… (full text at CIViC) PMID 28958504 · Catenacci et al., 2017 · Open in CIViC	civic

Gastric Adenocarcinoma1

MET Overexpression

Rilotumumab

Predictive

Does Not Support Sensitivity Response

accepted

EID5835

In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarc… (full text at CIViC)

PMID 28958504 · Catenacci et al., 2017 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma3
EGFR Mutation AND ( MET Amplification OR MET Overexpression )	Gefitinib + TepotinibCombination	Predictive	B	Supports Sensitivity Response	2	submitted	EID11456 This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC) PMID 32479794 · Wu et al., 2020 · Open in CIViC	civic
MET Exon 14 Skipping Mutation OR MET Overexpression	AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11422 38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC) PMID 37041472 · Hu et al., 2023 · Open in CIViC	civic
MET Overexpression	(diagnostic)	Diagnostic	B	Supports Positive	4	submitted	EID11371 Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC) PMID 15735036 · Ma et al., 2005 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma3

EGFR Mutation AND ( MET Amplification OR MET Overexpression )

Gefitinib + TepotinibCombination

Predictive

Supports Sensitivity Response

submitted

EID11456

This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC)

PMID 32479794 · Wu et al., 2020 · Open in CIViC

civic

MET Exon 14 Skipping Mutation OR MET Overexpression

AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M

Predictive

Does Not Support Sensitivity Response

submitted

EID11422

38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC)

PMID 37041472 · Hu et al., 2023 · Open in CIViC

civic

MET Overexpression

(diagnostic)

Diagnostic

Supports Positive

submitted

EID11371

Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC)

PMID 15735036 · Ma et al., 2005 · Open in CIViC

civic

Lung Sarcomatoid Carcinoma1
MET Exon 14 Skipping Mutation AND MET Overexpression	Crizotinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID11382 A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC) PMID 26709483 · Lee et al., 2015 · Open in CIViC	civic

Lung Sarcomatoid Carcinoma1

MET Exon 14 Skipping Mutation AND MET Overexpression

Crizotinib

Predictive

Supports Sensitivity Response

submitted

EID11382

A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC)

PMID 26709483 · Lee et al., 2015 · Open in CIViC

civic

Uveal Melanoma4
MET Overexpression	Crizotinib	Predictive	D	Supports Sensitivity Response	1	accepted	EID1583 c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC) PMID 24140933 · Surriga et al., 2013 · Open in CIViC	civic
MET Overexpression	Crizotinib	Predictive	E	Supports Sensitivity Response	2	rejected	EID1582 Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC) PMID 25961751 · Sun et al., 2015 · Open in CIViC	civic
MET Overexpression	C-Met Inhibitor + ERBB3 Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID3037 MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC	civic
MET Overexpression	Selumetinib + TrametinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID3038 In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib,… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC	civic

Uveal Melanoma4

MET Overexpression

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID1583

c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC)

PMID 24140933 · Surriga et al., 2013 · Open in CIViC

civic

MET Overexpression

Crizotinib

Predictive

Supports Sensitivity Response

rejected

EID1582

Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC)

PMID 25961751 · Sun et al., 2015 · Open in CIViC

civic

MET Overexpression

C-Met Inhibitor + ERBB3 Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination

Predictive

Supports Sensitivity Response

submitted

EID3037

MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC)

PMID 25952648 · Cheng et al., 2015 · Open in CIViC

civic

MET Overexpression

Selumetinib + TrametinibSubstitutes

Predictive

Supports Resistance

accepted

EID3038

In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib,… (full text at CIViC)

PMID 25952648 · Cheng et al., 2015 · Open in CIViC

civic

Ovarian Clear Cell Carcinoma1unmapped disease
MET Overexpression	Cabozantinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7932 Transcriptome sequencing found ovarian clear cell carcinoma (CCC) tissue has 2.2-fold increased expression of MET compared to high-grade serous carcinoma (HGSC) cells. The effects of cabozantinib wer… (full text at CIViC) PMID 29061793 · Nakatani et al., 2017 · Open in CIViC	civic

Ovarian Clear Cell Carcinoma1unmapped disease

MET Overexpression

Cabozantinib

Predictive

Supports Sensitivity Response

submitted

EID7932

Transcriptome sequencing found ovarian clear cell carcinoma (CCC) tissue has 2.2-fold increased expression of MET compared to high-grade serous carcinoma (HGSC) cells. The effects of cabozantinib wer… (full text at CIViC)

PMID 29061793 · Nakatani et al., 2017 · Open in CIViC

civic

Evidence by cancer (14 items)

Clinical significance (0)